Biogen reports second positive Phase 2 trial of litifilimab in cutaneous lupus at AAD 2026
Cutaneous lupus, an autoimmune disease that inflames and scars the skin, has few targeted treatments. Biogen $BIIB reported a second positive Phase 2 trial of litifilimab, which significantly cut skin disease activity. Results were shown at the American Academy of Dermatology mee
Cutaneous lupus erythematosus is the skin form of lupus, an autoimmune disease in which the body attacks its own tissue. It produces painful rashes, inflammation and permanent scarring, often on the face, and for many patients the only options have been broad immune-suppressing drugs, steroids and antimalarials that do not always work. Biogen $BIIB has now reported a second positive Phase 2 trial of litifilimab, an experimental antibody therapy, in this condition. The company says the drug produced a significant reduction in skin disease activity compared with placebo. The results were presented at the 2026 annual meeting of the American Academy of Dermatology. What separates this from a one-off result is that it is the second positive Phase 2 in the same disease. Mid-stage trials are where most experimental drugs stumble, and a single positive readout can be a fluke. A second independent win makes the signal harder to dismiss and gives Biogen a firmer basis to design the larger Phase 3 trials that regulators require before approval. For patients who respond poorly to current care, a therapy aimed specifically at the immune activity behind the disease is what is being tested here. Litifilimab is still in mid-stage development and would need to clear Phase 3 trials before any regulatory approval. Source: Biogen company release and coverage of the American Academy of Dermatology 2026 annual meeting.